
样式: 排序: IF: - GO 导出 标记为已读
-
Optimal Pre-Transplant Duration with HeartMate III Left Ventricular Assist Device: A Contemporary Analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-16 Ahmet Bilgili,Iverson E Williams,Omar M Sharaf,Fabian Jimenez,Yuriy Stukov,Giles J Peek,Mark S Bleiweis,Jeffrey P Jacobs,Thomas M Beaver,Eric I Jeng
BACKGROUND This study evaluates the impact of pretransplant HeartMate III (HM3) left ventricular assist device (LVAD) support duration on post-transplant survival in a contemporary cohort. METHODS A retrospective review of the United Network for Organ Sharing database was conducted for adult heart transplant recipients from January 2019 to December 2023 who were bridged with an HM3 LVAD. We utilized
-
Corrigendum to ''Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)'' [J Heart Lung Transplant 43 (2024) 272-283]. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-14 Vallerie McLaughlin,Harrison W Farber,Kristin B Highland,Anna R Hemnes,Murali M Chakinala,Kelly M Chin,Michelle Han,Michelle Cho,Tobore Tobore,Mohammad Rahman,Nick H Kim
-
Correlation between Donor-Derived Cell-free DNA and Tissue Gene Expression in Heart Transplant Patients Undergoing for-cause Endomyocardial Biopsies. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-13 Andrea Fernandez Valledor,Cathrine M Moeller,Daniel Oren,Julia Baranowska,Salwa Rahman,Adi Hertz,Afsana Rahman,Carolyn Hennecken,Gal Rubinstein,Boaz Elad,Ilan Richter,Dor Lotan,Matthew Regan,Brian LaBarre,Adil Yunis,Justin Fried,Ersilia M DeFilippis,Paolo C Colombo,Melana Yuzefpolskaya,Jayant Raihkelkar,Farhana Latif,Kevin D Clerkin,David T Majure,Gabriel T Sayer,Nir Uriel
INTRODUCTION The introduction of donor-derived cell-free DNA (dd-cfDNA) and the Molecular Microscope (MMDx) is changing how we diagnose rejection following heart transplantation (HT). This study aims to assess the accuracy of dd-cfDNA in detecting rejection as identified by MMDx and histology, with a focus on determining an optimal dd-cfDNA threshold to improve diagnostic performance. METHODS Single-center
-
Belatacept as an Alternative Immunosuppressive Agent for Bone Marrow-Sparing in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-07 Stefanie J Hannan,Carlo J Iasella,Michel Sciullo,Cody Moore,Ryan Rivosecci,Lauren Sacha,Rachel M Sutton,Ritchie Koshy,Norihisa Shigemura,Pablo G Sanchez,Rafic Farah,Chadi A Hage,Jonathan K Alder,John F McDyer
As we have previously shown, Idiopathic pulmonary fibrosis lung transplant recipients (IPF-LTRs) with short-telomere length (STL) are prone to develop significant cytopenias and poor tolerance to cell cycle inhibitors, specifically Mycophenolate mofetil (MMF), post-transplant. We investigated the use of Belatacept as an alternative immunosuppressive agent in a prospective, open-label cohort of 9 ST-IPF-LTRs
-
Absolute Quantification of Donor-Derived Cell-Free DNA Following Pediatric and Adult Heart Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-07 Jens Böhmer,Håkan Wåhlander,Karin Tran-Lundmark,Michal Odermarsky,Maria Sjöborg Alpman,Julia Asp,Staffan Nilsson,Kristjan Karason,Sunnegårdh Jan,Anne Ricksten,Göran Dellgren
OBJECTIVE Traditional rejection surveillance after heart transplantation (HTx) is based on endomyocardial biopsies (EMB), which are invasive, expensive and associated with complications. Monitoring using cell-free DNA (cfDNA) is promising, but most studies report only on the donor fraction (DF) as the percentage of donor derived-cfDNA (dd-cfDNA) relative to total-cfDNA. We evaluated the performance
-
International experience of donation after circulatory death for lung transplantation. A special report from the International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-28 Michael Perch,Don Hayes,Wida S Cherikh,Alexandra Lewis,Lucinda Ewing,Eileen Hsich,Tajinder P Singh,Göran Dellgren,Rebecca Cogswell,
-
International experience of donation after circulatory death for heart transplantation: A special report from the International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-27 Eileen Hsich,Tajinder P Singh,Wida S Cherikh,Alexandra Lewis,Michael Perch,Don Hayes,Göran Dellgren,Rebecca Cogswell,
-
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-25 Tajinder P Singh,Eileen Hsich,Wida S Cherikh,Michael Perch,Don Hayes,Alexandra Lewis,Göran Dellgren,Rebecca Cogswell,
-
Activation of PANoptosis and ferroptosis during ex vivo lung perfusion in human lungs. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-25 Yajin Zhao,Lubiao Liang,Abby McCaig,Tanroop Aujla,Shaf Keshavjee,Mingyao Liu
BACKGROUND A recent study demonstrated upregulation of PANoptosis-related genes during reperfusion in human lung transplants. However, the impact of ex vivo lung perfusion (EVLP) on different cell death pathways and their relationship with inflammatory genes and clinical characteristics remains unknown. METHODS We conducted transcriptomic analyses on pre- and post-EVLP biopsies from 49 donation after
-
Low dose apixaban in HeartMate 3 LVAD patients, interim analysis of the ApixiVAD trial, a randomized controlled study. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-24 Bruno Schnegg,Ricardo Deveza,Sumita Barua,Sanjay Chavali,Phillip Lo,Lukas Capek,Jolie Bruno,Maryam Pavlicek-Bahlo,Eleni Xourgia,Alexandra Neagoe,Kathrin Zürcher,Kavitha Muthiah,Kaitlyn Lam,David Reineke,Matthias Siepe,Lukas Hunziker,Michele Martinelli,Peter Macdonald,Christopher Hayward
BACKGROUND Left ventricular assist devices (LVADs) improve outcomes in advanced heart failure but require anticoagulation. Vitamin K antagonists (VKAs) have significant limitations, with labile INRs and suboptimal Time in Therapeutic Range (TTR), associated with increased morbidity and mortality. Direct oral anticoagulant therapy (DOAC) has been contraindicated in LVAD patients. METHOD The ApixiVAD
-
Rescue kidney post lung transplant, is the safety net saving the day? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-24 Chadi A Hage,Norihisa Shigemura
-
Vented and vetted: A new take on donor lung ventilation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-23 Laura L Donahoe,Shaf Keshavjee
-
Custodiol-N Versus Custodiol®: Results from A Prospective Noninferiority Randomised Single Blind, Multicenter Phase 3 Trial In Patients Undergoing Heart Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-23 A Aliabadi-Zuckermann,E Osorio-Jaramillo,C Knosalla,J Gummert,G Szabo,F Wittmann,R Yeter,R Schramm,J Goekler,F Hennig,M Morshuis,A Zuckermann
BACKGROUND Custodiol® is a well-established preservation solution for organ transplantation and was the basis for the development of Custodiol-N to improve graft preservation. Previous results in coronary artery bypass graft surgery have shown effective cardiac protection without safety concerns. This study aimed to evaluate the safety and ability of Custodiol-N to preserve cardiac grafts for heart
-
CD26/DPP-IV inhibitors and associations with chronic lung allograft dysfunction in a multicenter cohort. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-27 Alexander R Graham,Maria V Grau-Sepulveda,Erika J Bush Buckley,Daniel F Dilling,Albert Faro,Steven R Hays,Jerry L Kirchner,Carli J Lehr,Isabelle Moneke,Samuel Passarelli,Erin Tallarico,Abigail Thaxton,Grant A Turner,Bo Young H Yen,Megan L Neely,Laurie D Snyder
BACKGROUND CD26/dipeptidyl peptidase 4 inhibitors (gliptins) target proinflammatory pathways that contribute to the development of chronic lung allograft dysfunction (CLAD). We analyzed longitudinal clinical data from 6 North American lung transplant centers to elucidate the effect of gliptin exposure on CLAD development after lung transplantation. METHODS This cohort included 6 North American lung
-
Single-cell RNA sequencing of pig lung transplantation reveals macrophage ferroptosis in lung ischemia-reperfusion injury. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-20 Fenghui Zhuang,Ye Ning,Chongwu Li,Yunzhe Luo,Peigen Gao,Tao Wang,Chenyang Dai,Huikang Xie,Wenxin He,Junqi Wu,Chang Chen
BACKGROUND While current lung ischemia-reperfusion injury (IRI) research predominantly relies on small animal models, significant interspecies physiological disparities between rodents and humans frequently lead to translational failures of promising therapies. This translational gap underscores the critical need for developing large animal models in IRI pathophysiology studies. METHODS We developed
-
The white rabbit of heart transplantation: Alice's in Wonderlands solution to heart preservation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-17 Alexander M Bernhardt,Hermann Reichenspurner
-
Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-16 Elsa Brunet-Ratnasingham,Shivaram Yellamilli,Ruyin Guo,Rashmi Prava Mohanty,Allen Duong,Nicholas A Kolaitis,Steven R Hays,Rupal J Shah,Aida Venado,Julia A Maheshwari,Mary Ellen Kleinhenz,Lorriana E Leard,John McDyer,Tereza Martinu,Alexis J Combes,Daniel R Calabrese,Jonathan P Singer,John R Greenland
BACKGROUND Acute lung allograft dysfunction (ALAD) is a clinical syndrome of forced expiratory volume in 1-second (FEV1) decline concerning for chronic lung allograft dysfunction (CLAD) onset. Novel diagnostic tools are needed to identify those with ALAD who will progress to CLAD and to target appropriate therapies. We hypothesized that progressive ALAD would be associated with changes in small airway
-
Time-series tacrolimus trough level prediction using multivariate long short-term memory networks: Methodology and prospective validation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-01 Haruki Choshi,Kentaroh Miyoshi,Maki Tanioka,Shinichi Toyooka
-
Longitudinal assessment of bone mineral density changes after heart transplant: Implications for DXA screening frequency. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-01 Ronnie Sebro,Mahmoud Elmahdy,Ayanna Braxton
We evaluated the rate of bone mineral density (BMD) loss after heart transplant using dual-energy X-ray absorptiometry (DXA) to determine the optimal DXA surveillance frequency. This retrospective study involved 153 heart transplant recipients aged 50 years or greater, followed for up to 5,614 (median 1,111) days after transplant. Mixed-effects models with random intercepts were used to evaluate BMD
-
Machine learning model for tacrolimus dosing: Can we validate and compare to existing options? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-05-01 Michael G S Shashaty,Gary E Weissman,Marc H Scheetz,Todd A Miano
-
Evaluating the influence of atrial fibrillation in chronic thromboembolic pulmonary hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-11 Sathineni Ashwin Reddy,Joanna Pepke-Zaba
-
Corrigendum to ''Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials'' [The Journal of Heart and Lung Transplantation, 44 (2025) 135-146]. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-09 Stephan Rosenkranz,Hossein-Ardeschir Ghofrani,Marius M Hoeper,David Langleben,Sara Hegab,Claudia Rahner,Jean-François Richard,Vallerie V McLaughlin
-
Paediatric Lung Transplantation for Childhood Interstitial Lung Disease: Indications and Outcome. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-08 Hendrik Schneider,Fabio Ius,Carsten Müller,Jawad Salman,Katharina Schütz,Harald Köditz,Katja Nickel,Gesine Hansen,Dmitry Bobylev,Nicolaus Schwerk,Julia Carlens
BACKGROUND Childhood interstitial lung disease (chILD) is heterogeneous, associated with significant morbidity and can cause organ failure. In these cases, lung transplantation (LuTx) is a treatment option. Data on indications and outcome after LuTx for chILD is limited. We compared characteristics of LuTx for chILD to the indications cystic fibrosis (CF) and pulmonary hypertension (PH). METHODS chILD-patients
-
Donor care units in heart transplantation: The heart of the matter. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-04 Ioannis Mastoris,David D'Alessandro
-
Rescue kidneys in lung transplantation: A retrospective analysis of recipients who might have benefitted from a kidney safety net. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-03 Jiashu Xue,Reed Jenkins,Jessica Ruck,Christian Merlo,Errol Bush
BACKGROUND In 2023, a new United Network for Organ Sharing (UNOS) policy established criteria for a kidney allocation safety net for lung transplant recipients (LTRs) with chronic renal dysfunction. We sought to evaluate the demographics and outcomes of past lung transplant recipients who would have been eligible for a rescue kidney under the new criteria. METHODS Using the UNOS Organ Procurement and
-
A randomized trial of open lung protective ventilation compared to conventional mechanical ventilation in deceased organ donors. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-03 Lorraine B Ware,Tatsuki Koyama,Ciara M Shaver,Sharon Swain,John Nguyen,Ahmad Salehi,Gundeep Dhillon,Nancy Wickersham,Julia Maheshwari,Jonathan P Singer,S Samuel Weigt,Jasleen Kukreja,Michael A Matthay
PURPOSE We conducted a randomized trial of open lung protective ventilation (OLPV) compared to conventional ventilation (CV) in deceased donors. The primary outcome was lung utilization for transplantation. METHODS Eligible donors were ≥13 years with PaO2/FiO2 between 150 and 400 mmHg. Donors were randomized to volume control with OLPV [tidal volume (TV) 8 ml/kg, PEEP 10 cmH2O, protocolized recruitment
-
An immersive look into temperature-controlled hypothermic heart preservation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-02 Fuyi Liao,Andrew E Gelman
-
Right atrial size in PAH: Independent marker or just an echo of RV dysfunction? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-02 Tor Skibsted Clemmensen,Mads Jønsson Andersen
-
The United Kingdom's experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Luke John Lloyd Williams,Rachel Hogg,Miguel Angel Reyes Roque,Sarah Beale,Mubassher Husain,Anand Jothidasan,Bart Zych,Vicky Gerovasili,Pradeep Kaul,Steven Tsui,Hassiba Smail,Ahmed Al Adhami,Jasvir Parmar,Stephen Pettit,Sri Aurovind Periasamy,Prashant Mohite,Philip Curry,Simon Messer,Karim Morcos,Rajamiyer Venkateswaran,Vipin Mehta,Vamsidhar Dronavalli,B C Ramesh,Aaron Ranasinghe,David Quinn,Binu Raj
BACKGROUND Abdominal Normothermic Regional Perfusion (A-NRP) improves outcomes for transplanted abdominal organs from Donation after Circulatory Death (DCD) donors. Concerns have been raised about the effect of A-NRP on lungs procured during multi-organ donation. We present the UK experience of performing direct procurement (DRP) of lungs from DCD donors with A-NRP. METHODS Retrospective analysis of
-
Telehealth interventions to improve outcomes in lung transplant recipients: Primary results of the INSPIRE-III randomized clinical trial. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 James A Blumenthal,Stephanie Mabe,David Arthur,Courtney Frankel,Daphne C McKee,Samantha Morrison,Andrew Sherwood,Laurie D Snyder,Scott M Palmer,
BACKGROUND There is growing evidence that many patients undergoing lung transplantation report significant distress and low physical activity (PA), which might not improve despite lung transplantation and may be associated with worse clinical outcomes. Few studies have attempted to improve psychological outcomes and functional capacity and PA after transplant. METHODS Investigational Study of Psychological
-
Hemodynamic, echocardiographic, and demographic profiles of patients with chronic thromboembolic pulmonary hypertension and atrial fibrillation: A multicenter cohort study. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Marta Braksator,Marcin Kurzyna,Grzegorz Kopeć,Piotr Pruszczyk,Ewa Mroczek,Tatiana Mularek-Kubzdela,Ilona Skoczylas,Piotr Błaszczak,Łukasz Chrzanowski,Miłosz Jaguszewski,Katarzyna Mizia-Stec,Zbigniew Gąsior,Grzegorz Grześk,Wojciech Jacheć,Ewa Lewicka,Katarzyna Ptaszyńska-Kopczyńska,Michał Tomaszewski,Ewa Malinowska,Szymon Darocha,Marcin Waligóra,Magdalena Jachymek,Maciej Lewandowski,Małgorzata Peregud-Pogorzelska
BACKGROUND Atrial fibrillation (AFib) reduces the quality of life and increases hospitalization frequency in patients with pulmonary hypertension (PH). Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of PH with a specific pathophysiology, treatment methods, and demographics; however, the factors that correlate with AFib in this population have not yet been determined. This study aimed
-
Long-term outcomes of adults with congenital heart disease and 1.5 ventricle repair. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Alexander C Egbe,William R Miranda,Heidi M Connolly,Joseph A Dearani
BACKGROUND The 1.5 ventricle repair is a palliative procedure for patients with congenital heart disease with advanced right heart failure. There are limited data about patient selection and outcomes of this procedure. The purpose of this study was to describe the clinical and hemodynamic characteristics, and outcomes of adults with congenital heart disease (CHD) and 1.5 ventricle repair. METHOD We
-
CPR and donation after circulatory death: Is repetitive ischemic injury harmful? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Eileen M Hsich
-
A consensus-based framework for the psychosocial evaluation of pediatric candidates for cardiothoracic transplant and ventricular assist devices. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Debra S Lefkowitz,Kelli Triplett,Lauren Schneider,Kara West,Corinne Anton,Kelly E Rea,Micah Brosbe,Elizabeth S Christofferson,Lillian Christon,Nadine Kasparian,Alexandra Lamari-Fisher,Katie McIntyre,Jill Plevinsky,Scott Auerbach,Neha Bansal,Christian Benden,Molly Dugan,Jonathan Edelson,Jami Gross-Toalson,Gillian Mayersohn,Jenny Prufe,Rachel M White,Jenny Wichart,Jo Wray,Melissa K Cousino
The psychosocial evaluation plays an essential role in the multidisciplinary assessment of pediatric patients for thoracic organ transplantation or ventricular assist device (VAD) placement. However, there is considerable practice variation with regard to the content and process of the evaluation, with no known recent published guidelines. Furthermore, the pediatric evaluation necessarily differs from
-
Bridging gaps in pediatric device development: The power of ACTION - a collaborative learning network. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-04-01 Deepa Mokshagundam,David N Rosenthal,Lauren Smyth,Angela Lorts
Progress in the field of pediatric ventricular assist devices (VAD) have revolutionized the care and management of young patients with end-stage heart failure. However, innovation in pediatric medical devices is limited by financial and regulatory barriers due to the small and heterogenous target population. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) was established in 2017
-
Preconditioning donor lungs with lung-derived exosomes mitigates ischemia-reperfusion injury in a warm ischemia porcine DCD model. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-22 Rafaela V P Ribeiro,Salah E Altarabsheh,Daemiel L Segamanasinghe,Ismar W Lopez-Muralles,Ana S Garcia Moreno,Gustavo Knop,Fuad Al-Azzam,Jorge Mallea,Douglas G Brownfield,Aaron C Olson,Daniel F Gibbard,Yujia Jing,Ke Cheng,Sahar A Saddoughi
BACKGROUND Donation after circulatory death (DCD) donors remain an underutilized source in the United States due to concerns of ischemia-reperfusion injury (IRI) after prolonged ischemic times. Lung-derived exosomes have shown potential in mitigating pulmonary fibrosis by promoting lung repair. Here, we sought to investigate the potential of lung-derived exosomes to prevent and repair lung IRI. METHODS
-
Unlocking the black box of heart preservation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-21 Arezu Aliabadi-Zuckermann,Andreas Zuckermann
-
Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Kaitlyn M Tracy,Timothy R Harris,Mark Petrovic,Michael Cortelli,William Tucker,Sean François,Yutaka Shishido,Victoria Simon,Brandon Petree,Carl A Johnson,Wei K Wu,Nancy L Cardwell,Elizabeth Simonds,TiOluwanimi T Adesanya,Avery K Fortier,Kimya Raietparvar,Stuart R Landstreet,Nancy Wickersham,John D O'Neill,John Poland,Ashish S Shah,Stephen DeVries,Christian Crannell,Charles C Marboe,Rei Ukita,Caitlin
BACKGROUND Access to life-saving lung transplantation remains limited by a shortage of donor organs. We have previously described rehabilitation of discarded human donor lungs to a quality suitable for transplantation using cross-circulation of whole blood between xeno-support swine and human lungs. However, the immunologic implications of transplanting rehabilitated lungs remain unknown. METHODS Human
-
Comparison of the prognostic value of right atrial echocardiographic parameters in pulmonary arterial hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Danny Mohama,Pitchaya Worapongsatitaya,Bettia Celestin,Felipe Kazmirczak,Shadi P Bagherzadeh,Kurt W Prins,Sasha Z Prisco,E Kenneth Weir,Roham Zamanian,Francois Haddad,Thenappan Thenappan
Pulmonary arterial hypertension (PAH) guidelines advocate measures of area for right atrial (RA) dimensions, while echocardiographic guidelines recommend RA volume. We compared the prognostic value of RA echocardiographic parameters to predict transplant-free survival in 332 adult patients with PAH. RA area correlated strongly with volume (r = 0.96). After adjusting for age and sex, for every 1-standardized
-
Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failure. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Michael B Keller,David Newman,Muhtadi Alnababteh,Ann Bon,Lucia Ponor,Pali Shah,Joby Mathew,Hyesik Kong,Temesgen Andargie,Woojin Park,Ananth Charya,Helen Luikart,Tyler Intrieri,Shambhu Aryal,Steven D Nathan,Jonathan B Orens,Kiran K Khush,Moon Jang,Sean Agbor-Enoh
BACKGROUND Current International Society for Heart and Lung Transplantation (ISHLT) criteria for pulmonary antibody-mediated rejection (AMR) is predicated on a constellation of clinical, laboratory and histopathological parameters, including the presence of donor-specific antibodies (DSA). However, molecular evidence of allograft injury is not considered. The aim of this study was to investigate if
-
Severe primary graft dysfunction of the transplanted heart-more than a single category? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Eleni Tseliou,Josef Stehlik
-
How relevant is xenogeneic cross-circulation as a model to repair human donor organs? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Yajin Zhao,Mingyao Liu
-
Surgical technique for repair of partial right anomalous pulmonary venous drainage during orthotopic heart transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-20 Brittany A Potz,Ruchika Kamojjala,Benjamin Yang,Anthony Zaki,Tara Karamlou,Hani K Najm
-
Considerations of ethical aspects of xenotransplantation in pediatric patients. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-19 Simon Urschel,Christian Benden,Savitri Fedson
With recent advances in xenotransplantation, an increased initiative toward clinical applications in human recipients has evolved. Along with this trend, ethical concerns and considerations have been discussed. Infants and young children have been suggested as a group of patients for consideration of early clinical application given their limited mechanical circulatory support options, high waitlist
-
Evaluating the mechanism of action behind controlled hypothermic preservation of donor hearts: A randomized pilot study. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-19 Allen A Razavi,Jon Kobashigawa,Aleksandr Stotland,Qiudong Chen,Jignesh Patel,Dominic Emerson,James Mirocha,Michael E Bowdish,Pedro Catarino,Dominick Megna,Tyler Gunn,Matthew Rafiei,Deepika Rai,Yang Song,Olayiwola Babalola,Adam Daniels,Michelle Kittleson,Evan Kransdorf,Andriana Nikolova,Lawrence Czer,Joanna Chikwe,Roberta A Gottlieb,Fardad Esmailian
BACKGROUND Controlled hypothermic preservation of donor hearts is associated with decreased post-transplant primary graft dysfunction compared to conventional cold storage. However, mechanisms underlying this benefit in human subjects are unclear. METHODS We randomized 20 heart transplant recipients at a single institution to receive donor hearts preserved with either controlled hypothermic preservation
-
Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-19 Ismail Cenik,Jan Van Slambrouck,Annalisa Barbarossa,Cedric Vanluyten,Xin Jin,Elena Prisciandaro,An-Lies Provoost,Christelle M Vandervelde,René Novysedlák,Ömer Serçik,Paul De Leyn,Hans Van Veer,Lieven Depypere,Yanina Jansen,Jacques Pirenne,Dirk E Van Raemdonck,Laurens J Ceulemans
BACKGROUND Ischemia-reperfusion injury (IRI) remains an important challenge in lung transplantation (LTx). Ischemia can be divided into 3 phases: cooling during procurement, preservation, and rewarming during implantation. Temperature fluctuations influence metabolic processes, exacerbating IRI. However, actual lung temperatures have not been previously studied. Therefore, we aimed to characterize
-
Commentary on autoantibodies and de novo donor HLA-specific antibodies in chronic lung allograft dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-19 Sandhya Bansal,Thalachallour Mohanakumar
-
Impact of renal failure requiring postoperative dialysis on lung transplant outcomes: A national registry study in children. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-17 Wonshill Koh,JanDong Seo,Nicholas J Ollberding,Don Hayes
BACKGROUND Renal dysfunction is a common postoperative complication following cardiothoracic surgery, including heart and lung transplantation. Among adult lung transplant (LTx) recipients, acute kidney injury is associated with increased morbidity and mortality with those requiring renal replacement therapy having the worst outcome. The prevalence and risk factors for renal failure requiring post-transplant
-
Reasons for donor heart offer refusal are often unrelated to the donor itself - when, why, and the "weekend effect". J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-13 Brian Wayda,Helen Luikart,Yingjie Weng,Shiqi Zhang,Nikole Neidlinger,R Patrick Wood,Javier Nieto,Bruce Nicely,John Belcher,Tahnee Groat,Darren Malinoski,Jonathan Zaroff,Kiran K Khush
BACKGROUND Most donor hearts offered for heart transplant (HT) in the United States (US) are turned down. We aimed to understand the reasons for this - focusing on those related to the potential recipient and HT center (i.e. donor-unrelated reasons for refusal). METHODS The Donor Heart Study (DHS) enrolled 4,333 adult potential heart donors in US from 2015 - 2020. Separately by donor, each HT center
-
The effect of bend relief perforations upon extrinsic graft obstruction risk - a histological analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-12 Balakrishnan Sivaraman,Chris Cotter,Kevin Bourque,Steve Briana,Brendan Malloy,Kartik Sundareswaran,Robert Kormos,Staci Jessen Horn,Kirsten Landsgaard,Fred Clubb
Extrinsic Outflow Graft Obstruction (EOGO) is a potential complication of durable left ventricular assist device (LVAD) therapy characterized by obstructive biodebris accumulation between the outflow graft (OG) and, in the case of HM3, the bend relief (BR). Recent reports have suggested that perforating the HM3 BR may help prevent EOGO. The study objective was to histologically compare the nature and
-
Response to hypercapnia as a tool to assess cardiac recovery in a porcine model of DCD heart transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-11 Georgia Beer,Manuel Egle,Selianne Graf,Adrian Segiser,Alexia Clavier,Anja Helmer,Rahel Ottersberg,Marina Mäusli,Kady Fischer,Dominik P Guensch,Alexander Kadner,Matthias Siepe,Sarah Longnus
The advent of normothermic, ex-situ heart perfusion (ESHP) enables new options for evaluation of cardiac grafts. Donation after circulatory death (DCD) is a promising solution to improve heart transplantation rates, but current ESHP evaluation approaches are recognized as suboptimal for DCD grafts. We aimed to develop a vascular function test for cardiac graft assessment during ESHP using a porcine
-
Gastroesophageal Reflux is a Risk Factor for the Development of de novo Donor Specific Antibodies after Lung Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-11 Peter Bell,Jeffrey Kiernan,Rayoun Ramendra,Stella Wang,Ella Huszti,Frank D'Ovidio,Jonathan Yeung,Elliot Wakeam,Marcelo Cypel,Shaf Keshavjee,Stephen Juvet,Lianne Singer,Colleen Parker,Louis Liu,Tereza Martinu,Meghan Aversa
BACKGROUND Despite evidence that gastroesophageal reflux (GER) is harmful to the lung allograft, the mechanism of injury remains incompletely defined. We hypothesized that GER induces a humoral alloimmune response and examined the association between GER and de novo donor-specific antibody (DSA) development. METHODS 508 lung transplant recipients who underwent routine pH-impedance testing at 3 months
-
Metabolic and transcriptomic insights into temperature controlled hypothermic preservation of human donor hearts. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-11 Gaurav Sharma,Ryan J Vela,LaShondra Powell,Stanislaw Deja,Xiaorong Fu,Shawn C Burgess,Craig R Malloy,Michael E Jessen,Matthias Peltz
BACKGROUND Heart transplantation (HT) is the gold standard for end-stage heart disease. Donor heart preservation is an important factor that influences post-transplant success. Recently, temperature-controlled storage has demonstrated reduced primary graft dysfunction compared to standard cold storage though mechanisms are poorly understood. We hypothesized that alterations in gene expression and metabolomics
-
Design and rationale for the clinical investigation of a novel, magnetically levitated left ventricular assist device for the treatment of refractory heart failure. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-08 Francis D Pagani,Jennifer A Cowger,Ulrich P Jorde,Christopher Salerno,Yoshifumi Naka,Geetha Bhat,Carmelo Milano,Vitaly Druker,James W Long,
BACKGROUND Contemporary durable left ventricular assist devices (LVAD) have established current benchmarks for patient outcomes, but introduction of more novel technology is lacking. The BrioVAD System (BrioHealth Solutions, Burlington, MA) is an innovative, fully magnetically levitated pump intended to provide short-term (ST) and long-term (LT) mechanical circulatory support. METHODS The Investigation
-
DCD heart transplantation in patients with vs without durable LVAD: One of these things is not like the other. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-07 Molly Silkowski,Anthony P Carnicelli
-
Regional differences in primary graft dysfunction: A report from the international consortium on PGD. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-06 J Guzman-Bofarull,E Ródenas-Alesina,Y Moayedi,L Truby,M Rivas-Lasarte,F Foroutan,J Han,S Fan,R Moayedifar,D Couto-Mallon,H Luikart,E Henricksen,G Kim,S Hall,J Felius,A DeVore,K Takeda,J B Lerman,M Sabatino,M Tremblay-Gravel,P Noly,R Miller,A Zuckermann,L Potena,M Crespo-Leiro,J Segovia-Cubero,S Chih,M J Farr,H Ross,K Khush,M Farrero
BACKGROUND The impact of regional differences on primary graft dysfunction (PGD) after heart transplantation (HT) has not been assessed. This study aims to compare differences in the incidence, risk factors, and outcomes of severe PGD in the US, Canada, and Europe. METHODS This retrospective, observational study included consecutive adult HT recipients from 14 centers between 2010-2022. The primary
-
Preparing the future of organ banking in heart transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-05 Cristiano Amarelli
-
"A physician who underwent heart transplant surgery: Lessons learned". J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-05 Alin Gragossian
This is a perspective of what it was like going through the diagnosis of advanced heart failure and subsequent heart transplant surgery in 2019.
-
Cell-free DNA in ex-vivo lung perfusate is associated with low-quality lungs and lung transplant outcome. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-04 Haruchika Yamamoto,Gavin W Wilson,Adam Sundby,Siyi Zhu,Jonathan Allen,Bonnie T Chao,Akhi Akhter,Shaf Keshavjee,Andrew Sage,Jonathan C Yeung
BACKGROUND Cell-free DNA (cfDNA) in ex-vivo lung perfusion (EVLP) perfusate has been shown to potentially reflect lung injury; however, the relationship between cfDNA concentration with clinical EVLP lung outcomes has not been elucidated. METHODS A discovery cohort of n = 100 clinical EVLP cases and a validation cohort (n = 50) were used in this single-center, retrospective cohort study. cfDNA was
-
Invited commentary: Harnessing multi-omics for lung IRI drug discovery. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2025-03-04 Norihisa Shigemura